NHS England has today (4 March 2016) launched a 30 day public consultation on a proposed number of new products for specialised services, (including service specifications and clinical commissioning policies). There has already been extensive engagement on these national specifications and policies, as they have been developed with the support and input of lead clinicans and patient and public representatives. This approach has helped ensure that the views of key stakeholders have informed and influenced the development of the specifications and policies to date. Please note this is one of several public consultations on a proposed number of new draft products for specialised services. We now wish to test them further with wider groups of stakeholders.
Chemosaturation for liver metastases from ocular melanomas:
Everolimus for prevention of organ rejection following heart transplantation:
Selexipag in the treatment of Pulmonary Arterial Hypertension:
Riociguat for Pulmonary Arterial Hypertension:
Infliximab for the treatment of hidradenitis suppurativa:
Rituximab for Immunobullous Disease:
Rituximab for cytopaenia complicating primary immunodeficiency:
Share
Share on Twitter Share on Facebook